Sutro Biopharma’s (STRO) “Outperform” Rating Reiterated at Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Sutro Biopharma (NASDAQ:STRO) in a research note released on Wednesday, Benzinga reports. Oppenheimer currently has a $10.00 price objective on the stock.

STRO has been the subject of a number of other research reports. HC Wainwright decreased their price target on Sutro Biopharma from $16.00 to $12.00 and set a buy rating for the company in a research report on Tuesday. Wedbush decreased their price target on Sutro Biopharma from $12.00 to $8.00 and set an outperform rating for the company in a research report on Tuesday. Finally, JMP Securities restated a market outperform rating and set a $17.00 price objective on shares of Sutro Biopharma in a research report on Tuesday. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of Buy and an average price target of $13.71.

Sutro Biopharma Stock Up 14.6 %

NASDAQ:STRO opened at $5.65 on Wednesday. Sutro Biopharma has a 1-year low of $2.01 and a 1-year high of $6.13. The firm has a market capitalization of $352.79 million, a price-to-earnings ratio of -3.17 and a beta of 0.95. The stock has a fifty day simple moving average of $4.53 and a 200 day simple moving average of $3.79.

Insider Buying and Selling at Sutro Biopharma

In other Sutro Biopharma news, insider Nicki Vasquez sold 12,185 shares of Sutro Biopharma stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $5.00, for a total transaction of $60,925.00. Following the transaction, the insider now owns 12,803 shares of the company’s stock, valued at approximately $64,015. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Sutro Biopharma

Several large investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Sutro Biopharma by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 2,890,000 shares of the company’s stock worth $12,398,000 after purchasing an additional 21,238 shares during the last quarter. Virtu Financial LLC acquired a new stake in Sutro Biopharma in the 4th quarter worth approximately $72,000. Exome Asset Management LLC acquired a new stake in Sutro Biopharma in the 4th quarter worth approximately $659,000. Barclays PLC lifted its holdings in Sutro Biopharma by 111.0% in the 4th quarter. Barclays PLC now owns 132,059 shares of the company’s stock worth $566,000 after purchasing an additional 69,480 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its holdings in Sutro Biopharma by 1.7% in the 4th quarter. Nuveen Asset Management LLC now owns 215,728 shares of the company’s stock worth $925,000 after purchasing an additional 3,583 shares during the last quarter. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.